Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05943990 · ClinicalTrials.gov registry record · Phase 1
Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
A Phase 1 study, sponsored by Adaptimmune.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT05943990 is a Phase 1 study that was terminated before completion, run by Adaptimmune. The registered enrollment target is 5 participants.
The verdict
NCT05943990, a Phase 1 study, was terminated before completion, sponsored by Adaptimmune.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
To assess the safety, tolerability and determine recommended phase 2 dose (RP2D) of GSK3845097 in HLA-A\*02:01, HLA-A\*02:05 and/or HLA-A\*02:06 positive participants with New York esophageal squamous cell carcinoma (NY-ESO)-1 and/or Cancer testis antigen 2 (LAGE-1a) positive, previously treated, advanced (metastatic or unresectable) Synovial Sarcoma (SS) and Myxoid/Round Cell Liposarcoma (MRCLS).
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG GSK3845097
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-12-21 |
| Est. Completion | 2022-10-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05943990
The ClinicalTrials.gov registry entry for NCT05943990 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adaptimmune, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT05943990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05943990 about?
NCT05943990 is a clinical study titled "Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma". To assess the safety, tolerability and determine recommended phase 2 dose (RP2D) of GSK3845097 in HLA-A\*02:01, HLA-A\*02:05 and/or HLA-A\*02:06 positive participants with New York esophageal squamous cell carcinoma (NY-ESO)-1 and/or Cancer testis antigen 2 (LAGE-1a) positive, previously treated, ad...
What is the current status of trial NCT05943990?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2020-12-21. Estimated completion is 2022-10-24.
What interventions are being tested in trial NCT05943990?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), GSK3845097 (DRUG).
Who is sponsoring clinical trial NCT05943990?
This trial is sponsored by Adaptimmune, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.